MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb MAGNETISMM-3
Verified

What's the purpose of this trial?

The purpose of the study is to evaluate whether single-agent PF-06863135 can provide clinical benefit in participants with relapsed/refractory multiple myeloma. PF-06863135 is a bispecific antibody: binding of PF-06863135 to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.

This trial is currently open and accepting patients.


What's being studied?

  • Elranatamab is a B-Cell Maturation Antigen (BCMA) CD-3 bispecific antibody being tested in multiple myeloma.

Additional Trial Information

Phase 2

Enrollment: 150 patients (estimated)

View More

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required. Create your account or call us today for help (888) 828-2206.

  • Inclusion Criteria:

    • Diagnosis of multiple myeloma (IMWG criteria, Rajkumar et al, 2014)
    • Measurable disease, as defined by at least 1 of the following:
      1. Serum M-protein >0.5 g/dL by SPEP
      2. Urinary M-protein excretion >200 mg/24 hours by UPEP
      3. Serum immunoglobulin FLC≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio
    • Refractory to at least one IMiD
    • Refractory to at least one PI
    • Refractory to at least one anti-CD38 antibody
    • Relapsed/refractory to last anti-myeloma regimen
    • ECOG performance status ≤2
    • Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1
    • Not pregnant and willing to use contraception

    Exclusion Criteria:

    • Smoldering multiple myeloma
    • Active Plasma cell leukemia
    • Amyloidosis
    • Active HBV, HCV, SARS-CoV2, HIV, or any active, uncontrolled bacterial, fungal, or viral infection
    • Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.
    • Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer)
View Additional Criteria

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

California

Beverly Hills Cancer Center

Beverly Hills, CA

Not Yet Accepting

Indiana

Franciscan Health

Indianapolis, IN

Not Yet Accepting

Kentucky

Norton Cancer Institute St. Matthews Campus

Louisville, KY

Open and Accepting

South Carolina

Saint Francis Hospital Cancer Center

Greenville, SC

Not Yet Accepting

Trial Links

Read the latest news and updates on this trial.

Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Pfizer to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors